BriaCell Therapeutics Corp.

AI-generated fair value estimate for this company.

Method: Risk-adjusted sum-of-the-parts NPV: $22.8M net cash (no debt) plus risk-adjusted NPV of Bria-IMT (Phase 3 immunotherapy in treatment-resistant metastatic breast cancer: $400M unrisked peak sales, 20% probability of success, 25% peak operating margin, 4x NPV multiple, discounted 5 years at an 18% biotech/micro-cap rate); 8.70M shares outstanding.

Reasoning: BriaCell is pre-revenue with a single pivotal Phase 3 asset and under one year of cash runway, so a traditional FCF DCF is not meaningful; a risk-adjusted rNPV plus net cash better reflects its binary, financing-dependent profile. I used an elevated 18% discount rate versus typical biotech (12%) to price in near-term dilution risk from the thin cash position, and a conservative 20% probability of success since the Phase 3 trial has not yet read out its primary endpoint.